Publications

Histone deacetylase inhibitors (HDACi) are valued treatment options for patients with T-cell malignancies. Romidepsin is a selective Class I HDACi initially approved for patients with relapsed or refractory (R/R) CTCL and PTCL. Romidepsin was withdrawn from its PTCL indication following a negative randomized Phase IV study (Ro-CHOP) that showed no benefit over CHOP alone, further diminishing options for patients. Herein, we describe the development of a first-in-class polymer nanoparticle (PNP) of romidepsin using an innovative amphiphilic di-block copolymer-based nanochemistry platform. Nanoromidepsin exhibited superior pharmacologic properties with improved tolerability and safety in murine models of T-cell lymphoma (TCL).